Q-omics provides the consensus-scored RAB34 profile across patient tissues and cancer cell-line models. RAB34 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB34 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RAB34 protein abundance shows 18,937 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight KIRC, HNSC, and COAD as cancer lineages where RAB34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB34 survival associations across molecular data types. RAB34 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB34 RNA expression–survival associations across cancer types. High RAB34 expression shows unfavorable associations in KIRC, MESO, STAD and LGG, but favorable associations in UVM and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB34 RNA expression.
This table summarizes RAB34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB34 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, THCA, LUAD and LIHC. The HNSC box plot shows higher RAB34 RNA expression in tumor versus normal tissue (log2 FC = +1.681, t-test p < 0.001).
This table shows molecular features associated with RAB34 in patient tissues and cancer cell lines. In patient samples, RAB34 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
